GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioSpecifics Technologies Corp (NAS:BSTC) » Definitions » PE Ratio (TTM)

BioSpecifics Technologies (BioSpecifics Technologies) PE Ratio (TTM) : 37.51 (As of Apr. 26, 2024)


View and export this data going back to 1991. Start your Free Trial

What is BioSpecifics Technologies PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-26), BioSpecifics Technologies's share price is $88.53. BioSpecifics Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was $2.36. Therefore, BioSpecifics Technologies's PE Ratio (TTM) for today is 37.51.


The historical rank and industry rank for BioSpecifics Technologies's PE Ratio (TTM) or its related term are showing as below:

BSTC' s PE Ratio (TTM) Range Over the Past 10 Years
Min: 14.03   Med: 26.26   Max: 69.29
Current: 34.93


During the past 13 years, the highest PE Ratio (TTM) of BioSpecifics Technologies was 69.29. The lowest was 14.03. And the median was 26.26.


BSTC's PE Ratio (TTM) is not ranked
in the Biotechnology industry.
Industry Median: 26.82 vs BSTC: 34.93

BioSpecifics Technologies's Earnings per Share (Diluted) for the three months ended in Sep. 2020 was $0.73. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was $2.36.

As of today (2024-04-26), BioSpecifics Technologies's share price is $88.53. BioSpecifics Technologies's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2020 was $2.36. Therefore, BioSpecifics Technologies's PE Ratio without NRI for today is 37.51.

During the past 13 years, BioSpecifics Technologies's highest PE Ratio without NRI was 69.29. The lowest was 14.03. And the median was 26.26.

BioSpecifics Technologies's EPS without NRI for the three months ended in Sep. 2020 was $0.73. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2020 was $2.36.

During the past 12 months, BioSpecifics Technologies's average EPS without NRI Growth Rate was -25.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was 26.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 35.20% per year.

During the past 13 years, BioSpecifics Technologies's highest 3-Year average EPS without NRI Growth Rate was 105.30% per year. The lowest was -59.90% per year. And the median was 21.10% per year.

BioSpecifics Technologies's EPS (Basic) for the three months ended in Sep. 2020 was $0.73. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2020 was $2.36.


BioSpecifics Technologies PE Ratio (TTM) Historical Data

The historical data trend for BioSpecifics Technologies's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSpecifics Technologies PE Ratio (TTM) Chart

BioSpecifics Technologies Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.70 34.61 26.73 22.08 16.55

BioSpecifics Technologies Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.22 16.55 15.36 23.64 22.20

Competitive Comparison of BioSpecifics Technologies's PE Ratio (TTM)

For the Biotechnology subindustry, BioSpecifics Technologies's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioSpecifics Technologies's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioSpecifics Technologies's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where BioSpecifics Technologies's PE Ratio (TTM) falls into.



BioSpecifics Technologies PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

BioSpecifics Technologies's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=88.53/2.360
=37.51

BioSpecifics Technologies's Share Price of today is $88.53.
BioSpecifics Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.36.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


BioSpecifics Technologies  (NAS:BSTC) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


BioSpecifics Technologies PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of BioSpecifics Technologies's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSpecifics Technologies (BioSpecifics Technologies) Business Description

Traded in Other Exchanges
N/A
Address
35 Wilbur Street, Lynbrook, NY, USA, 11563
BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.
Executives
Paul Gitman director 167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040
Michael Schamroth director 191 MEADOWVIEW AVENUE HEWLETT NY 11557
Toby Wegman director, 10 percent owner 4092 BOCAIRE BLVD. BOCA RATON FL 33487
Mark N Wegman director 43 OVERLOOK ROAD OSSINING NY 10562
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
Joseph Truitt director, officer: Chief Executive Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael A. Sherman director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fishman Corey N. director DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Patrick Hutchison officer: Chief Financial Officer C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
J Kevin Buchi director, officer: Chief Executive Officer 41 MOORES ROAD, FRAZER PA 19355
Patrick M Caldwell officer: Principal Financial Officer C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138
Jyrki Mattila director AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Ronald Edward Law officer: SVP Business Development 23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010
Thomas Wegman director, 10 percent owner, officer: President 1764 BRIAR PLACE MERRICK NY 11566
Estate Of Edwin H. Wegman 10 percent owner 4092 BOCAIRE BLVD. BOCA RATON FL 33487

BioSpecifics Technologies (BioSpecifics Technologies) Headlines

From GuruFocus